CN101429134A - 阿戈美拉汀的新晶形vi、它的制备方法和包含它的药物组合物 - Google Patents

阿戈美拉汀的新晶形vi、它的制备方法和包含它的药物组合物 Download PDF

Info

Publication number
CN101429134A
CN101429134A CNA2008101749182A CN200810174918A CN101429134A CN 101429134 A CN101429134 A CN 101429134A CN A2008101749182 A CNA2008101749182 A CN A2008101749182A CN 200810174918 A CN200810174918 A CN 200810174918A CN 101429134 A CN101429134 A CN 101429134A
Authority
CN
China
Prior art keywords
crystalline form
agomelatine
preparation
formula
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2008101749182A
Other languages
English (en)
Other versions
CN101429134B (zh
Inventor
G·科克雷尔
J·里诺尔
L·勒佩皮
J-P·勒库夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101429134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN101429134A publication Critical patent/CN101429134A/zh
Application granted granted Critical
Publication of CN101429134B publication Critical patent/CN101429134B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及式(I)化合物的晶形VI，该晶形以其X－射线粉末衍射图表征。阿戈美拉汀的新晶形VI、它的制备方法和包含它的药物组合物。

Description

阿戈美拉汀的新晶形VI、它的制备方法和包含它的药物组合物
技术领域
本发明涉及阿戈美拉汀或式(I)的N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺的新晶形VI：
它的制备方法以及包含它的药物组合物。
背景技术
阿戈美拉汀，或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺，具有有价值的药理性质。
它确实具有双重的特征，一方面，它是褪黑素能系统受体的激动剂，另一方面，它是5-HT2C受体的拮抗剂。这些性质使得它在中枢神经系统中具有活性，更特别是在重症抑郁、季节性情感障碍、睡眠障碍、心血管病理学、消化系统病理学、由时差导致的失眠和疲劳、食欲障碍和肥胖症的治疗中有活性。
阿戈美拉汀、它的制备和它的治疗用途在欧洲专利说明书EP 0 447285中已有描述。
鉴于该化合物的药学价值，获得纯度优良且尤其是重现性极好的形式是最重要的，该形式在溶出和方便配制方面显示出有价值的特性，允许其长时间储存而没有对温度、光、湿度或氧气水平的特别要求。
发明内容
本申请人现已开发了获得完好的、可重现的晶形的方法，所述晶形在溶出和方便配制方面显示出有价值的特性。另外，该新形式随着时间的过去具有非常显著的稳定性，允许其最适宜储存而无需特别的防备，这在制药工业构成了最重要的优势。
更特别的是，本发明涉及式(I)化合物的晶形VI，其通过以下X-射线粉末衍射图表征，应用Bruker D5000matic衍射计(铜对阴极)测定并且以术语晶面间距d、布拉格2θ角和相对强度(以相对于最强射线的百分数表示)表示：
Figure A200810174918D00051
式(I)化合物的晶形VI也通过以下红外光谱表征：可观察到的峰为907.5cm-1、866.7cm-1、852.8cm-1、827.4cm-1、754.6cm-1、734.6cm-1、698.4cm-1、672.1cm-1、650.9cm-1、611.9cm-1、588.1cm-1。
本发明还涉及制备式(I)化合物的晶形VI的方法，该方法的特征在于将阿戈美拉汀的异丙醚溶液在沸腾下加热，然后快速冷却至0℃。真空过滤后获得纯形式的形式VI。
在本发明的结晶方法中，可能应用通过任何方法获得的式(I)化合物。
本发明还涉及制备式(I)化合物的晶形VI的另一种方法，该方法的特征在于在环境温度下、在高压下将阿戈美拉汀在水/乙醇混合物(50/50体积/体积)中结晶24小时。
优选在本发明的第二种结晶方法中，在10kbar高压下将阿戈美拉汀重结晶。
在本发明的第二种结晶方法中，可能应用通过任何方法获得的式(I)化合物。
获得这种晶形的优点是其允许制备具有一致且可重现的组合物的药物制剂，其随着时间的过去具有极好的稳定性。
对如此获得的形式VI的药理学研究已经显示它在中枢神经系统和微循环方面具有基本活性，这使其被确立可用于治疗下列疾病：紧张、睡眠障碍、焦虑、重症抑郁、季节性情感障碍、心血管病理学、消化系统病理学、由时差导致的失眠和疲劳、精神分裂症、惊恐发作、忧郁症、食欲障碍、肥胖症、失眠、疼痛、精神病障碍、癫痫、糖尿病、帕金森病、老年性痴呆、与正常或病理性老化有关的多种障碍、偏头痛、记忆丧失、阿尔茨海默病以及脑循环障碍。在另一个活性领域中，表明阿戈美拉汀的形式VI可用于治疗性功能障碍，具有排卵抑制和免疫调节的性质，并且可潜在用于治疗癌症。
阿戈美拉汀的晶形VI优选用于治疗重症抑郁、季节性情感障碍、睡眠障碍、心血管病理学、消化系统病理学、由时差导致的失眠和疲劳、食欲障碍和肥胖症。
本发明还涉及药物组合物，该药物组合物包含作为活性成分的式(I)化合物的晶形VI以及一种或多种适宜的惰性无毒赋形剂。在本发明的药物组合物中，可以更特别提及的是适于口服、非肠道(静脉内或皮下)或经鼻施用的那些，片剂或糖锭剂、颗粒剂、舌下片、胶囊剂、锭剂、栓剂、乳膏剂、软膏剂、皮肤凝胶剂、可注射制剂、可饮用混悬剂和咀嚼胶。
有用剂量可以根据障碍的性质和严重性、施用途径以及患者的年龄和体重而不同。剂量在每天0.1mg至1g之间变化，一次或多次施用。
具体实施方式
下文实施例说明本发明，但不以任何方式限制本发明。
实施例1：N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺的晶形VI
将0.74g的N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺和36.06g的异丙醚装入试管中。将该悬浮液在沸腾下加热(温度73℃)2小时。然后快速冷却至0℃。在0℃下1小时后，经多孔3号玻璃滤器真空过滤。将获得的固体通过其熔点和以下X-射线粉末衍射图表征，应用Bruker D5000matic衍射计(铜对阴极)测定并且以术语晶面间距d、布拉格2θ角和相对强度(以相对于最强射线的百分数表示)表示：
Figure A200810174918D00071
熔点：94℃
红外光谱：907.5cm-1、866.7cm-1、852.8cm-1、827.4cm-1、754.6cm-1、734.6cm-1、698.4cm-1、672.1cm-1、650.9cm-1、611.9cm-1、588.1cm-1。
实施例2：N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺的晶形VI
在25℃下，将2g的N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺加入至20mL水/乙醇混合物(50/50体积/体积)中。将该悬浮液经多孔4号玻璃滤器过滤。将该N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺的饱和溶液置于10kbar压力下。24小时后，结晶完成并且将获得的固体通过其熔点和以下X-射线粉末衍射图表征，应用Bruker D5000matic衍射计(铜对阴极)测定并且以术语晶面间距d、布拉格2θ角和相对强度(以相对于最强射线的百分数表示)表示：
Figure A200810174918D00072
熔点：94℃
红外光谱：907.5cm-1、866.7cm-1、852.8cm-1、827.4cm-1、754.6cm-1、734.6cm-1、698.4cm-1、672.1cm-1、650.9cm-1、611.9cm-1、588.1cm-1。
实施例3：药物组合物
制备1000片的配方，每片包含25mg活性成分：
实施例1或2化合物.........................25g
乳糖一水合物..............................62g
硬脂酸镁..................................1.3g
玉米淀粉...................................26g
麦芽糖糊精.................................9g
无水胶态二氧化硅...........................0.3g
预胶化玉米淀粉，A型........................4g
硬脂酸.....................................2.6g
实施例4：药物组合物
制备1000片的配方，每片包含25mg活性成分：
实施例1或2化合物.......................25g
乳糖一水合物............................62g
硬脂酸镁................................1.3g
聚维酮..................................9g
无水胶态二氧化硅........................0.3g
甘醇酸纤维素钠..........................30g
硬脂酸..................................2.6g

Claims (7)

1.式(I)的阿戈美拉汀的晶形VI
Figure A200810174918C00021
其通过以下X-射线粉末衍射图表征，应用Bruker D5000matic衍射计(铜对阴极)测定并且以术语晶面间距d、布拉格2θ角和相对强度(以相对于最强射线的百分数表示)表示：
Figure A200810174918C00022
2.式(I)的阿戈美拉汀的晶形VI
Figure A200810174918C00023
其通过以下红外光谱表征：907.5cm-1、866.7cm-1、852.8cm-1、827.4cm-1、754.6cm-1、734.6cm-1、698.4cm-1、672.1cm-1、650.9cm-1、611.9cm-1、588.1cm-1。
3.制备权利要求1或2的式(I)化合物的晶形VI的方法，其特征在于将阿戈美拉汀的异丙醚溶液在沸腾下加热，快速冷却至0℃，然后真空过滤。
4.制备权利要求1或2的式(I)化合物的晶形VI的方法，其特征在于在环境温度下、在高压下将阿戈美拉汀在水/乙醇混合物(50/50体积/体积)中结晶24小时。
5.药物组合物，该药物组合物包含作为活性成分的权利要求1或2的阿戈美拉汀的晶形VI，以及一种或多种可药用惰性无毒载体。
6.权利要求5的药物组合物，其用于制备治疗褪黑素能系统障碍的药物。
7.权利要求5的药物组合物，其用于制备治疗睡眠障碍、紧张、焦虑、季节性情感障碍或重症抑郁、心血管病理学、消化系统病理学、由时差导致的失眠和疲劳、精神分裂症、惊恐发作、忧郁症、食欲障碍、肥胖症、失眠、疼痛、精神病障碍、癫痫、糖尿病、帕金森病、老年性痴呆、与正常或病理性老化有关的多种障碍、偏头痛、记忆丧失、阿尔茨海默病、脑循环障碍或性功能障碍，作为排卵抑制剂或免疫调节剂或治疗癌症的药物。
CN2008101749182A 2007-11-09 2008-10-24 阿戈美拉汀的晶形vi、它的制备方法和包含它的药物组合物 Expired - Fee Related CN101429134B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR07/07861 2007-11-09
FR0707861A FR2923482B1 (fr) 2007-11-09 2007-11-09 Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
CN101429134A true CN101429134A (zh) 2009-05-13
CN101429134B CN101429134B (zh) 2012-05-23

Family

ID=39535664

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008101749182A Expired - Fee Related CN101429134B (zh) 2007-11-09 2008-10-24 阿戈美拉汀的晶形vi、它的制备方法和包含它的药物组合物

Country Status (45)

Country Link
US (1) US8067639B2 (zh)
EP (1) EP2058296B1 (zh)
JP (1) JP2009137943A (zh)
KR (1) KR20090048364A (zh)
CN (1) CN101429134B (zh)
AR (1) AR071253A1 (zh)
AU (1) AU2008243132B2 (zh)
BR (1) BRPI0804994A2 (zh)
CA (1) CA2643622C (zh)
CL (1) CL2008003316A1 (zh)
CO (1) CO6120149A1 (zh)
CR (1) CR10406A (zh)
CU (1) CU20080200A7 (zh)
CY (1) CY1118196T1 (zh)
DK (1) DK2058296T3 (zh)
EA (1) EA015402B1 (zh)
EC (1) ECSP088859A (zh)
ES (1) ES2608961T3 (zh)
FR (1) FR2923482B1 (zh)
GE (1) GEP20125579B (zh)
HK (1) HK1131777A1 (zh)
HR (1) HRP20161672T1 (zh)
HU (1) HUE030048T2 (zh)
IL (1) IL194931A (zh)
JO (1) JO3178B1 (zh)
LT (1) LT2058296T (zh)
MA (1) MA30464B1 (zh)
ME (1) ME02701B (zh)
MX (1) MX2008013782A (zh)
MY (1) MY148319A (zh)
NI (1) NI200800294A (zh)
NZ (1) NZ572636A (zh)
PE (1) PE20090912A1 (zh)
PL (1) PL2058296T3 (zh)
PT (1) PT2058296T (zh)
RS (1) RS55316B1 (zh)
SA (1) SA08290715B1 (zh)
SG (1) SG152991A1 (zh)
SI (1) SI2058296T1 (zh)
SV (1) SV2008003088A (zh)
TW (1) TWI356051B (zh)
UA (1) UA97478C2 (zh)
UY (1) UY31419A1 (zh)
WO (1) WO2009095555A1 (zh)
ZA (1) ZA200809358B (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102554A1 (zh) * 2009-03-10 2010-09-16 上海医药工业研究院 阿戈美拉汀的新晶型ⅵ及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN102001959A (zh) * 2009-09-01 2011-04-06 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
WO2011075943A1 (zh) * 2009-12-23 2011-06-30 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN102206864A (zh) * 2011-04-13 2011-10-05 吉林省博大伟业制药有限公司 阿戈美拉汀的ⅵ晶型单晶及混合晶型和制备方法
WO2012126386A1 (zh) * 2011-03-23 2012-09-27 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934856B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede d'obtention de la forme cristalline v de l'agomelatine
EP2319827A1 (en) 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine
EP2558440B1 (en) 2010-04-15 2016-11-16 ratiopharm GmbH Process for the production of polymorph form i of agomelatine
WO2012046253A2 (en) * 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms
CZ303787B6 (cs) 2011-01-21 2013-05-02 Zentiva, K.S. Metastabilní krystalové formy agomelatinu a jejich farmaceutické kompozice
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
WO2013082302A1 (en) 2011-11-30 2013-06-06 Ratiopharm Gmbh Agomelatine-urea complex and crystalline forms thereof
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
EP2872129B1 (en) 2012-07-16 2017-03-08 ratiopharm GmbH Complex of agomelatine and cyclodextrin
CN102988315B (zh) * 2012-09-28 2017-11-17 浙江华海药业股份有限公司 阿戈美拉汀固体制剂的制备方法
WO2014072998A1 (en) 2012-11-07 2014-05-15 Cadila Healthcare Limited An improved process for preparation of agomelatine
EP2934502A1 (en) 2012-12-21 2015-10-28 Laboratorios Lesvi S.L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
CZ2013621A3 (cs) 2013-08-13 2015-02-25 Zentiva, K.S. Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine
EP3466923A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
CN114028335A (zh) * 2021-12-24 2022-02-11 山东京卫制药有限公司 一种阿戈美拉汀溶液鼻喷剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1146164B (it) 1980-07-16 1986-11-12 Selenia Ind Elettroniche Dispositivo di filtraggio doppler adattivo alla situazione di clutter ed ecm esterna per impianti radar
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CZ2003529A3 (cs) * 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Krystalický a čistý modafinil a postup jeho přípravy
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7645905B2 (en) * 2005-08-03 2010-01-12 Les Laboratoires Servier Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US7635721B2 (en) * 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8614251B2 (en) 2009-03-10 2013-12-24 Les Laboratories Servier Crystalline form VI of agomelatine, preparation method and application thereof
WO2010102554A1 (zh) * 2009-03-10 2010-09-16 上海医药工业研究院 阿戈美拉汀的新晶型ⅵ及其制备方法和应用
EA019127B1 (ru) * 2009-03-10 2014-01-30 Ле Лаборатуар Сервье Новая кристаллическая форма vi агомелатина, ее получение и применение
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN101955440B (zh) * 2009-07-17 2014-04-09 江苏万特制药有限公司 一种阿戈美拉汀新晶型及其制备方法
CN102001959A (zh) * 2009-09-01 2011-04-06 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
CN102001959B (zh) * 2009-09-01 2014-07-02 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
WO2011075943A1 (zh) * 2009-12-23 2011-06-30 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
US9029420B2 (en) 2009-12-23 2015-05-12 Tianjin Taipu Pharmaceutical Science & Technology Development Co., Ltd. Agomelatine and pharmaceutical compositions thereof
WO2012126386A1 (zh) * 2011-03-23 2012-09-27 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
EA023278B1 (ru) * 2011-03-23 2016-05-31 Шанхай Инститьют Оф Фармасьютикл Индастри Кристаллический агомелатин (форма-viii), способ его получения, применение и содержащая его фармацевтическая композиция
CN102206864B (zh) * 2011-04-13 2012-10-03 吉林省博大伟业制药有限公司 阿戈美拉汀的ⅵ晶型单晶及混合晶型和制备方法
CN102206864A (zh) * 2011-04-13 2011-10-05 吉林省博大伟业制药有限公司 阿戈美拉汀的ⅵ晶型单晶及混合晶型和制备方法

Also Published As

Publication number Publication date
MY148319A (en) 2013-03-29
LT2058296T (lt) 2016-11-25
NI200800294A (es) 2011-01-12
EP2058296A1 (fr) 2009-05-13
MX2008013782A (es) 2009-05-08
SV2008003088A (es) 2010-02-17
SI2058296T1 (sl) 2017-02-28
AR071253A1 (es) 2010-06-09
UA97478C2 (ru) 2012-02-27
IL194931A0 (en) 2009-11-18
EP2058296B1 (fr) 2016-10-05
CN101429134B (zh) 2012-05-23
CO6120149A1 (es) 2010-01-29
CR10406A (es) 2009-01-27
PT2058296T (pt) 2016-10-25
IL194931A (en) 2013-08-29
AU2008243132B2 (en) 2013-01-10
EA200802119A1 (ru) 2009-08-28
HRP20161672T1 (hr) 2017-02-10
UY31419A1 (es) 2008-11-28
HK1131777A1 (en) 2010-02-05
HUE030048T2 (hu) 2017-04-28
ES2608961T3 (es) 2017-04-17
US8067639B2 (en) 2011-11-29
RS55316B1 (sr) 2017-03-31
AU2008243132A1 (en) 2009-05-28
DK2058296T3 (en) 2017-01-23
KR20090048364A (ko) 2009-05-13
GEP20125579B (en) 2012-07-25
FR2923482B1 (fr) 2010-01-29
PL2058296T3 (pl) 2017-03-31
SA08290715B1 (ar) 2012-05-16
TWI356051B (en) 2012-01-11
WO2009095555A1 (fr) 2009-08-06
CY1118196T1 (el) 2017-06-28
US20090069434A1 (en) 2009-03-12
ME02701B (me) 2017-10-20
FR2923482A1 (fr) 2009-05-15
EA015402B1 (ru) 2011-08-30
TW200936548A (en) 2009-09-01
CL2008003316A1 (es) 2009-12-18
ZA200809358B (en) 2010-07-28
ECSP088859A (es) 2009-02-27
CA2643622C (fr) 2013-12-10
JO3178B1 (ar) 2018-03-08
CA2643622A1 (fr) 2009-05-09
JP2009137943A (ja) 2009-06-25
PE20090912A1 (es) 2009-07-18
NZ572636A (en) 2010-03-26
BRPI0804994A2 (pt) 2009-07-21
SG152991A1 (en) 2009-06-29
MA30464B1 (fr) 2009-06-01
CU20080200A7 (zh) 2011-04-26

Similar Documents

Publication Publication Date Title
CN101429134B (zh) 阿戈美拉汀的晶形vi、它的制备方法和包含它的药物组合物
CN100448843C (zh) 阿戈美拉汀的新晶形ⅴ、它的制备方法和包含它的药物组合物
CN100445264C (zh) 阿戈美拉汀的新晶形ⅳ、它的制备方法和包含它的药物组合物
CN100450995C (zh) 阿戈美拉汀的新晶形ⅲ、它的制备方法和包含它的药物组合物
US7358395B2 (en) Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US20100076088A1 (en) Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US20100063158A1 (en) Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
KR100904116B1 (ko) 아고멜라틴의 ⅴ 결정형, 이의 제조 방법 및 이를 함유하는 약제 조성물
JPH10316677A (ja) 結 晶
KR20070017020A (ko) 아고멜라틴의 결정질 형태 ⅳ, 이의 제조 방법 및 이를함유하는 약제 조성물
KR20070017019A (ko) 아고멜라틴의 결정질 형태 ⅲ, 이의 제조 방법 및 이를함유하는 약제 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131777

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131777

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120523

Termination date: 20211024